Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Longitudinal Investigation of Imidazoline-2 Binding Site as a Novel Marker of Disease Progression in Parkinson's Disease: An [11C]BU99008 PET Study

NCT05516719 is registered in ClinicalTrials.gov with University of Exeter as lead sponsor.

NCT NCT05516719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05516719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Longitudinal Investigation of Imidazoline-2 Binding Site as a Novel Marker of Disease Progression in Parkinson's Disease: An [11C]BU99008 PET Study
Lead sponsor
University of Exeter
Phase
Observational
Overall status
Recruiting
Start date
November 1, 2021
Completion date
June 30, 2026
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neurodegeneration, neurodegenerative diseases, parkinson disease, parkinson's, parkinson's disease, positron emission tomography